Preclinical CRO Strength IITRI operates as a mid-size, not-for-profit preclinical contract research organization with extensive capabilities in safety and toxicology, inhalation studies, and cancer therapeutics, supported by significant lab space and single-location operations. Potential sales angle: position IITRI as a trusted partner for IND-enabling toxicology and specialized safety studies for pharma, biotech, and government programs.

NCI Relationship IITRI is the largest commercial CRO contractor to the National Cancer Institute and has ongoing infectious disease and cancer biology expertise. Growth opportunity: target collaboration or expansion with NCI-funded programs, oncology drug development sponsors, and government-funded contracting requiring high-touch, rapid-study design.

Specialized Capabilities Core strengths include inhalation toxicology, biodefense and infectious disease studies, and translational cancer immunology. Sales approach: highlight end-to-end safety and efficacy testing, inhalation exposure modeling, and rapid study starts to sponsors prioritizing respiratory or biodefense countermeasures.

Geographic and Operational Focus All functions housed in a single Chicago facility with over 110,000 square feet of lab space, enabling integrated programs and streamlined communication. Value proposition: emphasize one-location cooperation, faster study initiation, and personalized project management for mid-sized sponsors.

Engagement and Growth Active participation in scientific conferences (ICAR, ACT) and collaboration with government programs (BARDA RRPV) indicate a proactive business development posture and exposure to potential funded opportunities. Sales takeaway: leverage conference presence and partnerships to introduce IITRI capabilities to decision-makers in biopharma, government, and defense sectors.